GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bal Pharma BALPHARMA.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

83.18

+2.00%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹3.12bn

FY2017FY2026

Net income

₹62.8m

FY2017FY2026

Free cash flow

−₹40.8m

FY2017FY2026

Shareholders' equity

₹822.3m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹3.12bn₹3.03bn₹3.39bn₹3.04bn₹2.81bn₹2.47bn₹1.71bn₹2.25bn₹2.09bn₹2.29bn
Research and development—₹32.5m₹50.7m₹49.2m₹32.0m₹31.7m₹28.3m₹16.4m₹16.4m₹14.8m
Operating income₹227.5m₹219.9m₹243.1m₹169.3m₹253.2m₹162.6m−₹26.1m₹117.1m₹121.5m₹77.4m
Net income₹62.8m₹72.2m₹73.9m₹25.7m₹56.1m₹47.4m−₹122.2m₹37.9m₹27.8m₹19.9m
Diluted earnings per share3.954.535.071.633.793.20-10.792.671.971.39

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₹3.76bn₹3.36bn₹3.20bn₹3.13bn₹2.61bn₹2.40bn₹2.38bn₹2.61bn₹2.52bn₹2.30bn
Cash and short-term investments₹92.9m₹105.2m₹199.3m₹74.6m₹60.8m₹39.7m₹35.1m₹41.5m₹40.4m₹46.4m
Total liabilities₹2.93bn₹2.58bn₹2.50bn₹2.49bn₹2.02bn₹1.87bn₹1.93bn₹2.01bn₹1.92bn₹1.70bn
Debt₹1.60bn₹1.50bn₹1.42bn₹1.33bn₹1.07bn₹1.14bn₹1.20bn₹1.24bn₹1.10bn₹931.1m
Shareholders' equity₹822.3m₹774.2m₹692.9m₹637.9m₹586.3m₹535.8m₹524.3m₹666.4m₹649.9m₹629.9m
Shares outstanding16m16m15m16m15m15m11m14m14m14m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations₹144.7m₹42.3m₹228.1m−₹18.4m₹277.1m₹217.8m₹231.0m₹77.6m−₹5.0m₹58.6m
Capital spending−₹185.5m−₹187.9m−₹109.8m−₹146.5m−₹84.7m−₹34.1m−₹50.6m−₹85.9m−₹37.8m−₹83.8m
Free cash flow−₹40.8m−₹145.5m₹118.3m−₹164.9m₹192.4m₹183.7m₹180.4m−₹8.4m−₹42.8m−₹25.2m
Dividends paid−₹19.1m−₹19.1m−₹15.7m−₹15.6m−₹14.8m−₹2.9m−₹14.2m−₹14.7m−₹16.8m−₹16.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹886.2m₹840.8m₹876.9m₹740.2m₹658.7m₹818.8m₹731.5m₹736.9m
Operating income₹51.7m₹75.1m₹63.2m₹45.8m₹35.4m₹54.6m₹55.8m₹52.2m
Net income₹11.2m₹35.9m₹17.8m₹7.1m₹2.0m₹54.3m₹4.8m₹10.4m
Diluted earnings per share0.712.261.120.450.133.410.330.71
Cash from operations———₹101.0m—₹44.0m₹44.0m₹114.0m
Capital spending———−₹107.0m—−₹38.0m−₹38.0m−₹110.0m
Free cash flow———−₹6.0m—₹6.0m₹6.0m₹4.0m
Total assets—₹3.76bn—₹3.49bn—₹3.36bn₹3.36bn₹3.40bn
Cash and short-term investments₹92.9m₹92.9m₹91.3m₹106.6m₹105.2m₹105.2m₹104.1m₹261.6m
Debt—₹1.60bn—₹1.55bn—₹1.51bn₹1.20bn₹1.55bn
Shareholders' equity₹822.5m₹822.3m₹783.3m₹783.3m₹774.0m₹774.2m₹774.2m₹687.9m

Financial ratios

Data as of 4 Nov 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin7.3%7.3%6.5%5.1%5.3%6.6%—
Net margin2.0%2.4%2.2%0.8%2.0%1.9%—
Return on equity7.6%9.3%10.7%4.0%9.6%8.9%—
Return on assets1.7%2.1%2.3%0.8%2.2%2.0%—
Free cash flow yield25.3%17.6%28.2%9.9%29.7%20.7%—
Revenue growth2.8%-10.7%11.5%8.2%13.9%44.3%—
Earnings growth-12.9%-2.4%187.4%-54.2%18.3%-138.8%—
Current ratio1.05x1.07x1.15x1.09x1.11x1.08x—
Debt to equity1.94x1.95x2.03x2.07x1.78x2.06x—
Equity ratio21.9%23.1%21.7%20.4%22.5%22.3%—
Interest coverage1.35x1.30x1.44x1.45x1.42x1.34x—
R&D as a share of sales—1.1%1.5%1.6%1.1%1.3%1.7%
Buybacks as a share of market value0.0%-9.2%7.7%-6.6%0.0%-30.9%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue0.8%4.8%4.6%
Operating income10.3%6.9%11.0%
Net income34.7%5.8%16.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin7.3%6.8%7.1%5.8%
Net margin2.2%1.9%1.9%1.1%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings21.416.224.261.524.133.1-5.215.440.279.7
Price to sales0.40.40.50.50.50.60.40.30.50.7

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 18 Sept 2025.

FY2026FY2025FY2024FY2023FY2022FY2020FY2019FY2018
Paid in the year1.202.401.001.001.001.001.001.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.